Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta has completed a marketing authorization application for European regulators that seeks approval for the anticancer drug Genasense in combination with chemotherapy for the treatment of patients with advanced malignant melanoma.
Subscribe to our email newsletter
Review of the application is coordinated by the European medicines authority (EMEA). The procedure affords for a centralized authorization that is valid in all 25 member states of the European Community.
Genasense, Genta’s lead anticancer drug, is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of resistance to cancer treatment. By knocking down Bcl-2 in cancer cells, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma.
“We believe that Genasense represents a breakthrough treatment for patients, and we look forward to continued dialogue with regulatory authorities in Europe,” commented Dr Raymond Warrell Jr, chairman and CEO of Genta.